Chris Schott (1984-1988), Leisa Reed (1974-1978), Karen Stanley (1983-1987), Jack Wilhelmy (1957-1961), Chuck Miller (1979-1983), Kaleb Swarts (2004-2008)
Holly Froum and Negisa Balluku, Bloomberg Intelligence analysts, said last month that J&J may wind up paying as much as $10 billion to resolve its talc liability after the bankruptcys dismissal. Earlier this year, Chris Schott, a JPMorgan Chase & Co. analyst, estimated J&Js total talc
Date: Oct 18, 2023
Category: Business
Source: Google
Wall Street thought Mylan was headed for disaster—now, analysts are raving
ger picture, we see recent weakness in MYL as overdone, said J.P. Morgan analyst Chris Schott. We see Mylan as one of the better-positioned players in the space with a number of longer-term growth drivers in place (biosimilars, the pending genetic Advair approval, a significant ex-US business).
Date: Nov 06, 2018
Category: Headlines
Source: Google
How a Merck cancer breakthrough caused Bristol-Myers' stock to plunge
Morgans Chris Schott made a case for a Bristol recovery, saying that while the latest results were wholly disappointing, we see sentiment bottoming as we move past ESMO and continue to see an attractive long-term thesis based on the study of Opdivo in combination with cancer drug Yervoy, which h
Date: Oct 10, 2016
Category: Business
Source: Google
The long-anticipated Pfizer split-up won't happen, CEO says
Yes, other pharma industry hive-offs have done well; JP Morgan analyst Chris Schott pointed out Pfizers own animal health spinoff, Zoetis, on the call. Read himself mentioned AbbVie, the pharma unit that Abbott Laboratories split off in 2014. But those increases in value say as much about what was
Date: Sep 26, 2016
Category: Business
Source: Google
Pfizer's breast cancer drug is promising, clinical trial shows
Chris Schott, a JPMorgan Chase & Co. predicted a great sale for Ibrance once it hits the market. According to Schott, the successful trial of Ibrance will give it the advantage it needs to make it in the market.
Date: Apr 15, 2015
Category: Health
Source: Google
Teva Pharmaceutical Industries Ltd Mulls Next Move As Mylan NV Offers $29 ...
Mylan's announcement to go after Perrigo has come about after talks that a Mylan-Teva merger would be strategic for both the companies. In fact, Chris Schott, an analyst at JP Morgan Chase & Co., had discussed the idea of a combination of the two companies in a research note sent to clients just
Date: Apr 09, 2015
Category: Business
Source: Google
Mylan Makes Biggest Bid Yet: $29 Billion For Perrigo
Hours before the news broke, JPMorgan analyst Chris Schott theorized in a research note that Mylan could go for upward of $80 a share in such a deal. However, he added, "We believe Mylan could look at its own larger M&A transactions."
Date: Apr 08, 2015
Category: Business
Source: Google
Merck halts study in light of melanoma drug's success
P. Morgan analyst Chris Schott even called it a paradigm-shifting asset, especially given its potential to treat non-small cell lung cancer better than other existing options. Sales of PD-1 inhibitors could reach more than $10 billion a year just for non-small cell lung cancer, and Keytrudas peak
Date: Mar 24, 2015
Category: Health
Source: Google
Googleplus
Chris Schott
Education:
UCI - Engineering
Relationship:
Its_complicated
Chris Schott
Tagline:
My name is chris schott and i am a junior at mid east, im pretty fun to be around, so if u wanna hangout with me just ask!